Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bilastine PK study in Chinese population
NCT03633760Phase 1Unknown
- Sponsor
- Menarini Group
- Start
- Aug 2018
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of bilastine in allergic rhinoconjunctivitis (ARC) and urticaria (2 arms), sponsored by Menarini Group. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Concentration and 15 more. Status: unknown.
02
Drugs
bilastine
03
Conditions
allergic rhinoconjunctivitis (ARC)urticaria
Beyond the preview
Go deeper on NCT03633760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03633760.